RS62226B1 - Azasetron za upotrebu u lečenju gubitka sluha - Google Patents

Azasetron za upotrebu u lečenju gubitka sluha

Info

Publication number
RS62226B1
RS62226B1 RS20211004A RSP20211004A RS62226B1 RS 62226 B1 RS62226 B1 RS 62226B1 RS 20211004 A RS20211004 A RS 20211004A RS P20211004 A RSP20211004 A RS P20211004A RS 62226 B1 RS62226 B1 RS 62226B1
Authority
RS
Serbia
Prior art keywords
azasetron
treatment
hearing loss
hearing
loss
Prior art date
Application number
RS20211004A
Other languages
English (en)
Inventor
Jonas Dyhrfjeld-Johnsen
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Publication of RS62226B1 publication Critical patent/RS62226B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
RS20211004A 2015-05-18 2016-05-18 Azasetron za upotrebu u lečenju gubitka sluha RS62226B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562163177P 2015-05-18 2015-05-18
EP15167992 2015-05-18
EP16725074.5A EP3297628B1 (en) 2015-05-18 2016-05-18 Azasetron for use in the treatment of hearing loss
PCT/EP2016/061119 WO2016184900A1 (en) 2015-05-18 2016-05-18 Calcineurin inhibitors of the setron family for the treatment of hearing loss

Publications (1)

Publication Number Publication Date
RS62226B1 true RS62226B1 (sr) 2021-09-30

Family

ID=53199806

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211004A RS62226B1 (sr) 2015-05-18 2016-05-18 Azasetron za upotrebu u lečenju gubitka sluha

Country Status (12)

Country Link
US (2) US11433077B2 (sr)
EP (2) EP3297628B1 (sr)
JP (2) JP6994765B2 (sr)
CN (1) CN107847489B (sr)
CY (1) CY1124406T1 (sr)
ES (1) ES2882602T3 (sr)
HU (1) HUE056138T2 (sr)
PL (1) PL3297628T3 (sr)
PT (1) PT3297628T (sr)
RS (1) RS62226B1 (sr)
SI (1) SI3297628T1 (sr)
WO (1) WO2016184900A1 (sr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184900A1 (en) * 2015-05-18 2016-11-24 Sensorion Calcineurin inhibitors of the setron family for the treatment of hearing loss
MX2018012587A (es) 2016-04-14 2019-03-07 Sensorion (+)-azasetron para uso en el tratamiento de trastornos del oido.
WO2017178645A1 (en) * 2016-04-14 2017-10-19 Sensorion (+)-azasetron for use in the treatment of ear disorders
JP7044294B2 (ja) * 2017-09-21 2022-03-30 学校法人慶應義塾 音響外傷難聴モデル動物の作製用の音響暴露装置
CN112237009B (zh) 2018-01-05 2022-04-01 L·奥拉 助听器及其使用方法
US11095992B2 (en) * 2018-01-05 2021-08-17 Texas Institute Of Science, Inc. Hearing aid and method for use of same
CN108309964B (zh) * 2018-04-04 2020-06-30 军事科学院军事医学研究院环境医学与作业医学研究所 二甲双胍在制备噪声性听力损失防治产品中的应用
EP4003360A1 (en) 2019-07-25 2022-06-01 Sensorion Treatment and/or prevention of lesions in the central auditory nervous system
WO2023175078A1 (en) * 2022-03-16 2023-09-21 Sensorion Azasetron for the treatment of sudden sensorineural hearing loss

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1304082C (en) * 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
WO2003071986A2 (en) * 2002-02-22 2003-09-04 Control Delivery Systems, Inc. Method for treating otic disorders
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
AU2008298016B2 (en) * 2007-09-12 2012-02-02 Merz Pharma Gmbh & Co.Kgaa 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
EP2296632A4 (en) 2008-07-14 2014-11-12 Otonomy Inc APOPTOSEMODULATING COMPOSITIONS WITH TAXED RELEASE AND METHOD FOR TREATING EAR OR DISEASES
DE102009003232A1 (de) * 2009-05-19 2010-12-02 Federal-Mogul Burscheid Gmbh Gleitelement eines Verbrennungsmotors, insbesondere Kolbenring
JP5955767B2 (ja) 2009-05-20 2016-07-20 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
JP2015511242A (ja) * 2012-02-23 2015-04-16 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） 病変性前庭障害の治療に使用するカルシニューリン阻害剤
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
WO2016184900A1 (en) * 2015-05-18 2016-11-24 Sensorion Calcineurin inhibitors of the setron family for the treatment of hearing loss
MX2018012587A (es) * 2016-04-14 2019-03-07 Sensorion (+)-azasetron para uso en el tratamiento de trastornos del oido.

Also Published As

Publication number Publication date
PT3297628T (pt) 2021-08-16
PL3297628T3 (pl) 2021-12-06
EP3297628B1 (en) 2021-06-09
CN107847489B (zh) 2021-09-17
CN107847489A (zh) 2018-03-27
SI3297628T1 (sl) 2021-10-29
HUE056138T2 (hu) 2022-01-28
WO2016184900A1 (en) 2016-11-24
US20220387438A1 (en) 2022-12-08
JP6994765B2 (ja) 2022-02-10
US20180207167A1 (en) 2018-07-26
EP3909579A1 (en) 2021-11-17
ES2882602T3 (es) 2021-12-02
EP3297628A1 (en) 2018-03-28
US11433077B2 (en) 2022-09-06
CY1124406T1 (el) 2022-07-22
JP2018522938A (ja) 2018-08-16
JP2022028941A (ja) 2022-02-16

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
EP3160405A4 (en) Treatment of the ear
HUE056138T2 (hu) Azasetron a halláskárosodás kezelésében való felhasználásra
GB201608885D0 (en) Treatment
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
GB2543540B (en) Decellularising tissue
IL251904A0 (en) Epilimod for use in the treatment of melanoma
EP3362091A4 (en) COMBINATION THERAPY
IL266701A (en) An implant with several cavities
HK1247558A1 (zh) 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化
GB201519450D0 (en) Novel treatment
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
GB201508841D0 (en) Treatment
IL262305B (en) Azasterone for use in the treatment of disorders related to the ear
EP3323368A4 (en) TREATMENT TOOL
GB201503008D0 (en) Treatment
LT3297628T (lt) Azasetronas, skirtas naudoti klausos praradimo gydymui
GB201718985D0 (en) Treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment